JMP Securities Reiterates Market Outperform on Cormedix, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Cormedix (NASDAQ:CRMD) and maintained a price target of $19.
November 15, 2023 | 5:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jason Butler reaffirmed a 'Market Outperform' rating on Cormedix, with a maintained price target of $19.
The reiteration of a 'Market Outperform' rating and the maintenance of a $19 price target by a reputable analyst could lead to increased investor confidence in Cormedix, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100